• Western blot analysis of K562 cells using CyPB Polyclonal Antibody.. Secondary antibody was diluted at 1:20000

Anti-PPIB antibody (151-200 aa) (STJ96801)

SKU:
STJ96801

Current Stock:
Host: Rabbit
Applications: WB/ELISA
Reactivity: Human/Mouse/Rat
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Rabbit polyclonal antibody anti-Peptidyl-prolyl cis-trans isomerase B (151-200 aa) is suitable for use in Western Blot and ELISA research applications.
Clonality: Polyclonal
Conjugation: Unconjugated
Isotype: IgG
Formulation: Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide.
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration: 1 mg/mL
Dilution Range: WB 1:500-1:2000
ELISA 1:20000
Storage Instruction: Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.
Gene Symbol: PPIB
Gene ID: 5479
Uniprot ID: PPIB_HUMAN
Immunogen Region: 151-200 aa
Specificity: CyPB Polyclonal Antibody detects endogenous levels of CyPB protein.
Immunogen: The antiserum was produced against synthesized peptide derived from the C-terminal region of human PPIB at the amino acid range 151-200
Protein Name Peptidyl-Prolyl Cis-Trans Isomerase B
Ppiase B
Cyp-S1
Cyclophilin B
Rotamase B
S-Cyclophilin
Scylp
Database Links Reactome: R-HSA-1650814
Reactome: R-HSA-9692916
Cellular Localisation Virion
(Microbial Infection)
Endoplasmic Reticulum Lumen
Melanosome
Identified By Mass Spectrometry In Melanosome Fractions From Stage I To Stage Iv
Alternative Antibody Names Anti-Peptidyl-Prolyl Cis-Trans Isomerase B antibody
Anti-Ppiase B antibody
Anti-Cyp-S1 antibody
Anti-Cyclophilin B antibody
Anti-Rotamase B antibody
Anti-S-Cyclophilin antibody
Anti-Scylp antibody
Anti-PPIB antibody
Anti-CYPB antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance